{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T19:24:20Z","timestamp":1776453860269,"version":"3.51.2"},"reference-count":79,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1124\/jpet.122.001416","type":"journal-article","created":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T18:36:05Z","timestamp":1680287765000},"page":"190-197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Role of Gender Pharmacogenetics in the Personalization of Drug Treatment"],"prefix":"10.1016","volume":"386","author":[{"given":"Erika","family":"Cecchin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca","family":"Posocco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Mezzalira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marialuisa","family":"Appetecchia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Toffoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.122.001416_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.595219","article-title":"Pharmacogenetics guidelines: overview and comparison of the DPWG, CPIC, CPNDS, and RNPGx guidelines","volume":"11","author":"Abdullah-Koolmees","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1124\/jpet.122.001416_bib2","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.2217\/pgs.11.72","article-title":"Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity","volume":"12","author":"Amstutz","year":"2011","journal-title":"Pharmacogenomics"},{"key":"10.1124\/jpet.122.001416_bib3","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cpt.911","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update","volume":"103","author":"Amstutz","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.122.001416_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0074-7742(08)00001-9","article-title":"Gender differences in pharmacological response","volume":"83","author":"Anderson","year":"2008","journal-title":"Int Rev Neurobiol"},{"key":"10.1124\/jpet.122.001416_bib5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1089\/jwh.2005.14.19","article-title":"Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics","volume":"14","author":"Anderson","year":"2005","journal-title":"J Womens Health (Larchmt)"},{"key":"10.1124\/jpet.122.001416_bib6","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1515\/cclm-2012-0849","article-title":"Gender medicine: a task for the third millennium","volume":"51","author":"Baggio","year":"2013","journal-title":"Clin Chem Lab Med"},{"key":"10.1124\/jpet.122.001416_bib7","doi-asserted-by":"crossref","first-page":"10126","DOI":"10.1038\/s41598-022-13085-5","article-title":"Oxycodone\/naloxone versus tapentadol in real-world chronic non-cancer pain management: an observational and pharmacogenetic study","volume":"12","author":"Barrachina","year":"2022","journal-title":"Sci Rep"},{"key":"10.1124\/jpet.122.001416_bib8","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.biopsych.2021.02.972","article-title":"Sex-dependent shared and nonshared genetic architecture across mood and psychotic disorders","volume":"91","author":"Blokland","year":"2022","journal-title":"Biol Psychiatry"},{"key":"10.1124\/jpet.122.001416_bib9","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1001\/jama.296.15.1858","article-title":"National surveillance of emergency department visits for outpatient adverse drug events","volume":"296","author":"Budnitz","year":"2006","journal-title":"JAMA"},{"key":"10.1124\/jpet.122.001416_bib10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.urolonc.2013.09.002","article-title":"Essential elements of personalized medicine","volume":"32","author":"Burke","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1124\/jpet.122.001416_bib11","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/cpt.707","article-title":"Electronic medical record-integrated pharmacogenomics and related clinical decision support concepts","volume":"102","author":"Caraballo","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.122.001416_bib12","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41418-017-0051-x","article-title":"Sex disparity in cancer: roles of microRNAs and related functional players","volume":"25","author":"Car\u00e8","year":"2018","journal-title":"Cell Death Differ"},{"key":"10.1124\/jpet.122.001416_bib13","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/gim.2016.87","article-title":"Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC)","volume":"19","author":"Caudle","year":"2017","journal-title":"Genet Med"},{"key":"10.1124\/jpet.122.001416_bib14","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2174\/1389200215666140130124910","article-title":"Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process","volume":"15","author":"Caudle","year":"2014","journal-title":"Curr Drug Metab"},{"key":"10.1124\/jpet.122.001416_bib15","doi-asserted-by":"crossref","first-page":"204","DOI":"10.2174\/1389201018666170103103619","article-title":"Ubiquitous pharmacogenomics (U-PGx): the time for implementation is now. An Horizon2020 program to drive pharmacogenomics into clinical practice","volume":"18","author":"Cecchin","year":"2017","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1124\/jpet.122.001416_bib16","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/tpj.2013.30","article-title":"Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females","volume":"14","author":"Clarke","year":"2014","journal-title":"Pharmacogenomics J"},{"key":"10.1124\/jpet.122.001416_bib17","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1158\/1055-9965.EPI-20-0036","article-title":"Sex differences in cancer incidence and survival: a pan-cancer analysis","volume":"29","author":"Dong","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1124\/jpet.122.001416_bib18","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev-pharmtox-010814-124835","article-title":"Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers","volume":"55","author":"Dunnenberger","year":"2015","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/jpet.122.001416_bib19","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1200\/JCO.1994.12.11.2248","article-title":"Population study of dihydropyrimidine dehydrogenase in cancer patients","volume":"12","author":"Etienne","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1124\/jpet.122.001416_bib20","doi-asserted-by":"crossref","first-page":"474","DOI":"10.12688\/f1000research.14451.3","article-title":"Predicting lithium treatment response in bipolar patients using gender-specific gene expression biomarkers and machine learning","volume":"7","author":"Eugene","year":"2018","journal-title":"F1000 Res"},{"key":"10.1124\/jpet.122.001416_bib21","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2105\/AJPH.2011.300279","article-title":"Challenging assumptions about minority participation in US clinical research","volume":"101","author":"Fisher","year":"2011","journal-title":"Am J Public Health"},{"key":"10.1124\/jpet.122.001416_bib22","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/bph.12362","article-title":"Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women","volume":"171","author":"Franconi","year":"2014","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.122.001416_bib23","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/clpt.2008.144","article-title":"Is this the drug or dose for you? Impact and consideration of ethnic factors in global drug development, regulatory review, and clinical practice","volume":"84","author":"Huang","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.122.001416_bib24","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2217\/pgs-2021-0031","article-title":"Gender-dependent association of TYMS-TSER polymorphism with 5-fluorouracil or capecitabine-based chemotherapy toxicity","volume":"22","author":"Ioannou","year":"2021","journal-title":"Pharmacogenomics"},{"key":"10.1124\/jpet.122.001416_bib25","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1515\/dmpt-2021-0219","article-title":"MTHFR c.665C>T guided fluoropyrimidine therapy in cancer: gender-dependent effect on dose requirements","volume":"37","author":"Ioannou","year":"2022","journal-title":"Drug Metab Pers Ther"},{"key":"10.1124\/jpet.122.001416_bib26","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3390\/biomedicines8070232","article-title":"Sex and gender influences on cancer immunotherapy response","volume":"8","author":"Irelli","year":"2020","journal-title":"Biomedicines"},{"key":"10.1124\/jpet.122.001416_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2019.144050","article-title":"Pharmacogenes (PGx-genes): current understanding and future directions","volume":"718","author":"Katara","year":"2019","journal-title":"Gene"},{"key":"10.1124\/jpet.122.001416_bib28","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/s41397-021-00210-2","article-title":"The prevalence and clinical relevance of 2R\/2R TYMS genotype in patients with gastrointestinal malignancies treated with fluoropyrimidine-based chemotherapy regimens","volume":"21","author":"Khushman","year":"2021","journal-title":"Pharmacogenomics J"},{"key":"10.1124\/jpet.122.001416_bib29","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/cpt.543","article-title":"Improving therapeutic odyssey: preemptive pharmacogenomics utility in patient care","volume":"101","author":"Lazaridis","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.122.001416_bib30","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju298","article-title":"DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147)","volume":"106","author":"Lee","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1124\/jpet.122.001416_bib31","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1040-8428(02)00120-8","article-title":"Pharmacology of antineoplastic agents in older cancer patients","volume":"46","author":"Lichtman","year":"2003","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1124\/jpet.122.001416_bib32","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2217\/pgs-2020-0181","article-title":"Strategies and settings of clinical pharmacogenetic implementation: a scoping review of pharmacogenetics programs","volume":"22","author":"Luczak","year":"2021","journal-title":"Pharmacogenomics"},{"key":"10.1124\/jpet.122.001416_bib33","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/s41431-019-0540-0","article-title":"Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines","volume":"28","author":"Lunenburg","year":"2020","journal-title":"Eur J Hum Genet"},{"key":"10.1124\/jpet.122.001416_bib34","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2217\/14622416.8.3.271","article-title":"The potential of gender-specific tumor pharmacology","volume":"8","author":"Mader","year":"2007","journal-title":"Pharmacogenomics"},{"key":"10.1124\/jpet.122.001416_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.05.014","article-title":"Let\u2019s talk about sex: differences in drug therapy in males and females","volume":"175","author":"Madla","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1124\/jpet.122.001416_bib36","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2217\/pgs-2017-0093","article-title":"The Ubiquitous Pharmacogenomics consortium: making effective treatment optimization accessible to every European citizen","volume":"18","author":"Manson","year":"2017","journal-title":"Pharmacogenomics"},{"key":"10.1124\/jpet.122.001416_bib37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3892\/br.2017.922","article-title":"Personalized medicine could transform healthcare","volume":"7","author":"Mathur","year":"2017","journal-title":"Biomed Rep"},{"key":"10.1124\/jpet.122.001416_bib38","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1200\/JCO.1992.10.7.1171","article-title":"Influence of sex and age on fluorouracil clearance","volume":"10","author":"Milano","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1124\/jpet.122.001416_bib39","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/sj.bjc.6690098","article-title":"Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity","volume":"79","author":"Milano","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1124\/jpet.122.001416_bib40","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1073\/pnas.0730053100","article-title":"The melanocortin-1 receptor gene mediates female-specific mechanisms of analgesia in mice and humans","volume":"100","author":"Mogil","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.122.001416_bib41","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00280-012-2018-4","article-title":"Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study","volume":"71","author":"Mueller","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/jpet.122.001416_bib42","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1128\/AEM.72.2.1027-1033.2006","article-title":"Differences in fecal microbiota in different European study populations in relation to age, gender, and country: a cross-sectional study","volume":"72","author":"Mueller","year":"2006","journal-title":"Appl Environ Microbiol"},{"key":"10.1124\/jpet.122.001416_bib43","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.pharmthera.2011.11.002","article-title":"Cardiovascular pharmacogenetics","volume":"133","author":"Myburgh","year":"2012","journal-title":"Pharmacol Ther"},{"key":"10.1124\/jpet.122.001416_bib44","doi-asserted-by":"crossref","first-page":"E29","DOI":"10.1208\/ps050429","article-title":"Pharmacogenomics of multigenic diseases: sex-specific differences in disease and treatment outcome","volume":"5","author":"Pinsonneault","year":"2003","journal-title":"AAPS PharmSci"},{"key":"10.1124\/jpet.122.001416_bib45","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2174\/138920011795495321","article-title":"Clinically relevant genetic variations in drug metabolizing enzymes","volume":"12","author":"Pinto","year":"2011","journal-title":"Curr Drug Metab"},{"key":"10.1124\/jpet.122.001416_bib46","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1046\/j.0306-5251.2001.01498.x","article-title":"Pharmacogenetics and pharmacogenomics","volume":"52","author":"Pirmohamed","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/jpet.122.001416_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112234","article-title":"Association between migraine prevalence, treatment with proton-pump inhibitors and CYP2C19 phenotypes in UK Biobank","volume":"143","author":"Pisanu","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"10.1124\/jpet.122.001416_bib48","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/s41397-019-0118-9","article-title":"Gender based differences, pharmacogenetics and adverse events in chronic pain management","volume":"20","author":"Planelles","year":"2020","journal-title":"Pharmacogenomics J"},{"key":"10.1124\/jpet.122.001416_bib49","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/bcpt.12943","article-title":"Gender-specific association between ABCC2 -24C>T SNP and reduction in triglycerides in Chilean patients treated with atorvastatin","volume":"122","author":"Prado","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1124\/jpet.122.001416_bib50","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1365-2893.2011.01497.x","article-title":"IL28B genetic variants and gender are associated with spontaneous clearance of hepatitis C virus infection","volume":"19","author":"Rao","year":"2012","journal-title":"J Viral Hepat"},{"key":"10.1124\/jpet.122.001416_bib51","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature15817","article-title":"Pharmacogenomics in the clinic","volume":"526","author":"Relling","year":"2015","journal-title":"Nature"},{"key":"10.1124\/jpet.122.001416_bib52","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1681\/ASN.V11188","article-title":"Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen)","volume":"11","author":"Ruggenenti","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/jpet.122.001416_bib53","doi-asserted-by":"crossref","first-page":"11527","DOI":"10.1038\/s41598-019-47627-1","article-title":"Sex-related differences in impact on safety of pharmacogenetic profile for colon cancer patients treated with FOLFOX-4 or XELOX adjuvant chemotherapy","volume":"9","author":"Ruzzo","year":"2019","journal-title":"Sci Rep"},{"key":"10.1124\/jpet.122.001416_bib54","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1016\/S0140-6736(16)32392-3","article-title":"Editorial policies for sex and gender analysis","volume":"388","author":"Schiebinger","year":"2016","journal-title":"Lancet"},{"key":"10.1124\/jpet.122.001416_bib55","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1200\/JCO.2006.10.4182","article-title":"Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group","volume":"26","author":"Schwab","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1124\/jpet.122.001416_bib56","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1046\/j.1523-1755.2002.00624.x","article-title":"Interacting effects of gender and genotype on blood pressure response to hydrochlorothiazide","volume":"62","author":"Schwartz","year":"2002","journal-title":"Kidney Int"},{"key":"10.1124\/jpet.122.001416_bib57","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/nrc1887","article-title":"Drug interactions in cancer therapy","volume":"6","author":"Scripture","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1124\/jpet.122.001416_bib58","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1200\/JCO.2000.18.2.412","article-title":"Sex differences in fluorouracil-induced stomatitis","volume":"18","author":"Sloan","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1124\/jpet.122.001416_bib59","article-title":"Sex differences in drug disposition","volume":"2011","author":"Soldin","year":"2011","journal-title":"J Biomed Biotechnol"},{"key":"10.1124\/jpet.122.001416_bib60","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00003088-200948030-00001","article-title":"Sex differences in pharmacokinetics and pharmacodynamics","volume":"48","author":"Soldin","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/jpet.122.001416_bib61","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/1097-0142(19950101)75:1<11::AID-CNCR2820750104>3.0.CO;2-N","article-title":"Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial","volume":"75","author":"Stein","year":"1995","journal-title":"Cancer"},{"key":"10.1124\/jpet.122.001416_bib62","doi-asserted-by":"crossref","first-page":"e209","DOI":"10.1371\/journal.pmed.0040209","article-title":"Translating pharmacogenomics: challenges on the road to the clinic","volume":"4","author":"Swen","year":"2007","journal-title":"PLoS Med"},{"key":"10.1124\/jpet.122.001416_bib63","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/cpt.1049","article-title":"Pharmacogenetic information in clinical guidelines: the European perspective","volume":"103","author":"Swen","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.122.001416_bib64","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0140-6736(22)01841-4","article-title":"A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study","volume":"401","author":"Swen","year":"2023","journal-title":"Lancet"},{"key":"10.1124\/jpet.122.001416_bib65","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/sj.clpt.6100507","article-title":"Pharmacogenetics: from bench to byte","volume":"83","author":"Swen","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.122.001416_bib66","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.tips.2020.05.005","article-title":"In vitro and animal models for SARS-CoV-2 research","volume":"41","author":"Takayama","year":"2020","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/jpet.122.001416_bib67","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1542-2011.2010.00050.x","article-title":"Adverse drug reactions in women\u2019s health care","volume":"56","author":"Tharpe","year":"2011","journal-title":"J Midwifery Womens Health"},{"key":"10.1124\/jpet.122.001416_bib68","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1146\/annurev.pharmtox.47.120505.105150","article-title":"Idiosyncratic drug reactions: current understanding","volume":"47","author":"Uetrecht","year":"2007","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/jpet.122.001416_bib69","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/clpt.2013.229","article-title":"Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing","volume":"95","author":"Van Driest","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.122.001416_bib70","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/jnci\/djaa124","article-title":"Sex and adverse events of adjuvant chemotherapy in colon cancer: an analysis of 34\u2009640 patients in the ACCENT database","volume":"113","author":"Wagner","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"10.1124\/jpet.122.001416_bib71","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1093\/annonc\/mdz414","article-title":"Gender medicine and oncology: report and consensus of an ESMO workshop","volume":"30","author":"Wagner","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1124\/jpet.122.001416_bib72","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2174\/157016307781115485","article-title":"Pharmacogenomics of sex difference in chemotherapeutic toxicity","volume":"4","author":"Wang","year":"2007","journal-title":"Curr Drug Discov Technol"},{"key":"10.1124\/jpet.122.001416_bib73","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1038\/nature07336","article-title":"Innate immunity and intestinal microbiota in the development of Type 1 diabetes","volume":"455","author":"Wen","year":"2008","journal-title":"Nature"},{"key":"10.1124\/jpet.122.001416_bib74","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMra032424","article-title":"Drug metabolism and variability among patients in drug response","volume":"352","author":"Wilkinson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.122.001416_bib75","doi-asserted-by":"crossref","first-page":"5063","DOI":"10.1073\/pnas.1404203111","article-title":"Sex, equity, and science","volume":"111","author":"Woodruff","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.122.001416_bib76","doi-asserted-by":"crossref","DOI":"10.4172\/2157-7609.1000119","article-title":"Sex differences in the expression of drug-metabolizing and transporter genes in human liver","volume":"3","author":"Yang","year":"2012","journal-title":"J Drug Metab Toxicol"},{"key":"10.1124\/jpet.122.001416_bib78","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/S0959-8049(98)00259-7","article-title":"Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number","volume":"34","author":"Zalcberg","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.1124\/jpet.122.001416_bib79","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13293-020-00308-5","article-title":"Sex differences in pharmacokinetics predict adverse drug reactions in women","volume":"11","author":"Zucker","year":"2020","journal-title":"Biol Sex Differ"},{"key":"10.1124\/jpet.122.001416_bib80","article-title":"Pervasive neglect of sex differences in biomedical research","volume":"14","author":"Zucker","year":"2022","journal-title":"Cold Spring Harb Perspect Biol"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524170644?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524170644?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.122.001416","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T13:30:09Z","timestamp":1739971809000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524170644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":79,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0022356524170644"],"URL":"https:\/\/doi.org\/10.1124\/jpet.122.001416","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Role of Gender Pharmacogenetics in the Personalization of Drug Treatment","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.122.001416","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}